top of page
  • ODI Pharma

ODI Pharma AB publishes the annual report for the fiscal year 2021/2022

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2021/2022. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma ( and Spotlight Stock Market ( A Swedish translation of the annual report is also available on

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

ODI Pharma Annual Report 2021-2022 ENG_ updated 2022-11-25 vff
Download PDF • 4.20MB

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2022. The report is available as an attached document to this press release and on the Compa

Original on Transparent.png
bottom of page